Echo Therapeutics closes trial, preps for FDA submission in the "near future"

August 24, 2010 by MassDevice staff

Echo Therapeutics Inc. completes a clinical trial of its Prelude SkinPrep transdermal drug delivery system, saying it will seek 510(k) clearance from the Food & Drug Administration in the "near future."

ECTE logo

Echo Therapeutics Inc. (OTC:ECTE) announced the completion of a clinical trial of its Prelude SkinPrep transdermal drug delivery system, saying an application for 510(k) clearance from the Food & Drug Administration is imminent.

The Franklin, Mass.-based company launched the trial in April, in partnership with Ferndale Pharma Group Inc., to test the drug-device combination with Ferndale's 4 percent topical lidocaine. The needle-free system ablates a thin layer of skin before a drug is applied.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp